ETON News and Press, Eton Pharmaceutcials Inc. From 04/11/22

Eton Pharmaceuticals (NASDAQ:ETON) has added ~12% in the pre-market on Monday after the Deer Park, Illinois-based company announced that the U.S. Food and Drug Administration (FDA) issued final approval for its cysteine hydrochloride abbreviated new drug application (ANDA). The prod...

DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has received final approval from the U.S. Food and Drug Administ...

Eton Pharmaceuticals, Inc. (ETON) Q4 2021 Earnings Conference Call March 16, 2022 07:00 PM ET Company Participants David Krempa - Senior Vice President, Business Development & Investor Relations Sean Brynjelsen - Chief Executive Officer Wilson Troutman – Chief Financial Officer Kev...

Eton Pharmaceuticals press release (NASDAQ:ETON): Q4 GAAP EPS of $0.04 misses by $0.01. Revenue of $6.09M (+7512.5% Y/Y) misses by $1.47M. Shares +1.78%. For further details see: Eton Pharmaceuticals GAAP EPS of $0.04 misses by $0.01, revenue of $6.09M misses by $1.47M

Fourth Quarter 2021 Revenue of $6.1 million Fourth Quarter 2021 Net Income of $1.0 million and EPS of $0.04 DEER PARK, Ill., March 16, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializin...

Eton Pharmaceuticals (NASDAQ:ETON) is scheduled to announce Q4 earnings results on Wednesday, March 16th, after market close. The consensus EPS Estimate is $0.05 (+115.6% Y/Y) and the consensus Revenue Estimate is $7.56M (+9350.0% Y/Y). For further details see: Eton Pharmaceuticals Q4 2...

IDEX, LEN, WSM, PD, CPRX, NBEV, SYN, OTCQX:MRMD, REI, OTCQX:TRSSF, ZTO, ASM, SMTC, GES, LGO, SMTS, BAK, LMB, LFT, EDR, ETON, IMV, PANL For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Wednesday's close

Eton Pharmaceuticals (NASDAQ:ETON) and XGen Pharmaceuticals DJB commercially launched Rezipres (ephedrine hydrochloride) injection. Rezipres (4.7 mg/mL) is a ready-to-use formulation of injectable ephedrine hydrochloride approved to treat clinically important hypotension (low blood press...

DEER PARK, Ill., March 14, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres® (ephedrine hydrochloride) injection. Rezipres (4.7 mg/mL) is a ready-to-use 1 formulation of inj...

DEER PARK, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2021 financial results on Wednesday, ...